Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

1. Etanercept

Etanercept Top results for etanercept - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for etanercept The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Erelzi - Etanercept

Erelzi - Etanercept Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include post-authorization

Health Canada - Drug and Health Product Register2018

3. Brenzys, Etanercept

Brenzys, Etanercept Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1, 2012 will be updated to include post-authorization

Health Canada - Drug and Health Product Register2018

4. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott (...) N, Rodgers M & Rothery C. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Duarte A, Mebrahtu T, Goncalves P S, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M & Rothery C.. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology

Health Technology Assessment (HTA) Database.2018

5. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Adalimumab, etanercept and ustekinumab all offer some benefits for plaque psoriasis in children and young people but their cost per QALY is highly uncertain. {{author}} {{($index , , , , , , , & . Ana Duarte 1 , Teumzghi Mebrahtu 2 , Pedro Saramago Goncalves 1 , Melissa Harden 2 , Ruth Murphy 3 , Stephen Palmer 1 , Nerys Woolacott 2

NIHR HTA programme2017

6. Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment 28900875 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment. 391-404 10.1007/s40744-017-0079-x To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA (...) ) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab. All patients discontinued prior adalimumab treatment and continued methotrexate with etanercept 50 mg once weekly for 24 weeks. The primary study endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at week 12. Eighty-five patients (mean age 56.6 years; female 80.0%) were evaluated for safety and 84 for efficacy. Thirty (35.7%) patients achieved ACR20 at week 12

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

7. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Adalimumab, etanercept and Adalimumab, etanercept and ustekinumab for treating plaque psoriasis ustekinumab for treating plaque psoriasis in children and y in children and young people oung people T echnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Technology Appraisals2017

8. Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 21 April 2017 EMA (...) /CHMP/302222/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Erelzi International non-proprietary name: etanercept Procedure No. EMEA/H/C/004192/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/302222/2017 Page 2/81 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 8 2. Scientific

European Medicines Agency - EPARs2017

9. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. BACKGROUND: Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous research suggested clinical improvement with inhibition of interleukin 23 p19. We did two phase 3 trials to investigate whether tildrakizumab is superior (...) to placebo and etanercept in the treatment of chronic plaque psoriasis. METHODS: We did two three-part, parallel group, double-blind, randomised controlled studies, reSURFACE 1 (at 118 sites in Australia, Canada, Japan, the UK, and the USA) and reSURFACE 2 (at 132 sites in Europe, Israel, and the USA). Participants aged 18 years or older with moderate-to-severe chronic plaque psoriasis (body surface area involvement ≥10%, Physician's Global Assessment [PGA] score ≥3, and Psoriasis Area and Severity Index

Lancet2017

10. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes 28339738 2017 03 24 2017 05 26 1462-0332 56 6 2017 Jun 01 Rheumatology (Oxford, England) Rheumatology (Oxford) A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. 973-980 10.1093/rheumatology/kex003

EvidenceUpdates2017

11. Etanercept (Lifmior) - rheumatoid arthritis, certain forms of juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Etanercept (Lifmior) - rheumatoid arthritis, certain forms of juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 17 July 2017 EMA/114647/2016 Corr.1 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) report LIFMIOR International non-proprietary name: etanercept Procedure No. EMEA/H/C/004167/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/114647/2017 Page 2/19 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 Rheumatoid arthritis 4 Juvenile idiopathic arthritis 4 Psoriatic arthritis 4 Ankylosing spondylitis (AS) 5 Plaque psoriasis 5 Paediatric plaque psoriasis

European Medicines Agency - EPARs2017

12. Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept

Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept 28638688 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept. 136-138 10.5152/eurjrheum.2016.032 (...) A case of a 16-year-old female with polyarticular juvenile idiopathic arthritis (JIA) since the age of 4 years is reported here. This patient also suffered from multiple congenital anomalies. On long-term treatment with oral methotrexate (MTX) and etanercept, multiple subcutaneous nodules were detected, which were accompanied by increased lactate dehydrogenase and uric acid levels. A biopsy of the largest nodule revealed Epstein-Barr (EB) virus-positive diffuse large B-cell lymphoma (DLBCL

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

13. Etanercept (Subsequent Entry Biologic) (TBC)

Etanercept (Subsequent Entry Biologic) (TBC) Etanercept | CADTH.ca Find the information you need Etanercept Etanercept Last Updated: January 5, 2017 Result type: Reports Project Number: SE0513-000 Product Line: Generic Name: Etanercept Brand Name: Erelzi Manufacturer: Sandoz Canada Inc. Indications: Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis Submission Type: New Project Status: Active Files Follow us: © 2017 Canadian Agency for Drugs

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

14. Etanercept (TBC)

Etanercept (TBC) Etanercept | CADTH.ca Find the information you need Etanercept Etanercept Last Updated: January 5, 2017 Result type: Reports Project Number: SE0513-000 Product Line: Generic Name: Etanercept Brand Name: Erelzi Manufacturer: Sandoz Canada Inc. Indications: Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis Submission Type: New Project Status: Active Files Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

15. Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe 27817152 2018 11 13 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. 245-256 Benepali ® was the first etanercept (Enbrel ® ) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available (...) 16940305 Autoinjector Benepali Biosimilar Enbrel Etanercept Patients Rheumatoid arthritis Survey 2016 09 19 2016 11 7 6 0 2016 11 7 6 1 2016 11 7 6 0 ppublish 27817152 10.1007/s40744-016-0048-9 10.1007/s40744-016-0048-9 PMC5127972

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

16. Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe

Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe 27747586 2017 08 16 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali ® ) Versus Etanercept

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

17. ENBREL (etanercept), anti-TNF - juvenile idiopathic arthritis (JIA)

ENBREL (etanercept), anti-TNF - juvenile idiopathic arthritis (JIA) HUMIRA ENBREL AJI CT14088 CT14261 SUMMARY

Haute Autorite de sante2016

18. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis

The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis 27252426 2016 07 02 2017 02 03 0315-162X 43 7 2016 Jul The Journal of rheumatology J. Rheumatol. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. 1268-77 10.3899/jrheum.151179 An analysis of a clinical trial to assess the effects of treatment reduction and withdrawal (...) on patient-reported outcomes (PRO) in patients with early, moderate to severe rheumatoid arthritis (RA) who achieved 28-joint Disease Activity Score (DAS28) low disease activity (LDA) or remission with etanercept (ETN) plus methotrexate (MTX) therapy. During treatment induction, patients received open-label ETN 50 mg weekly plus MTX for 52 weeks. In the reduced-treatment phase, patients with DAS28-erythrocyte sedimentation rate (ESR) ≤ 3.2 at Week 39 and DAS28-ESR < 2.6 at Week 52 in the open-label phase

EvidenceUpdates2016

19. Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe

Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe 27747519 2018 11 13 2198-6576 3 1 2016 Jun Rheumatology and therapy Rheumatol Ther Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali ® ) Versus Etanercept (Enbrel ® ) - Findings (...) from a Nurse Survey in Europe. 77-89 10.1007/s40744-016-0035-1 Enbrel ® (etanercept: manufactured by Immunex Corporation, Newbury Park, Thousand Oaks, CA 91320, USA) was the first biological disease-modifying anti-rheumatic drug approved for the treatment of rheumatoid arthritis (RA) in Europe. More recently, an etanercept biosimilar (Benepali ® : manufactured by Biogen Inc, Cambridge, MA 02124, USA) was approved in the European Union. The perceptions and preferences of the Benepali autoinjector

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

20. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2016